"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

The study also leveraged advanced diagnostic tools to identify early biomarkers of cognitive decline in individuals with a ...

Blood biomarkers like p-tau217 are emerging as a way to detect Alzheimer's disease. The first FDA-approved blood-based ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer's drug—are poised ...

Alzheimer’s disease biomarkers measured from finger-prick dried blood samples closely match standard plasma tests and predict ...

Routine vaccinations offered to adults may help protect against dementia, recent research has shown.

For over a century, Alzheimer's disease (AD) has been considered irreversible. Consequently, research has focused on disease ...

A new study found that fixing energy balance in the brain reversed symptoms of advanced Alzheimer’s in mice.  Researchers ...

Finger-prick blood test accurately detects Alzheimer’s biomarkers, enabling at-home collection and broader research ...

Neumora Therapeutics (NMRA) stock jumps as the company posts early-stage trial data for its experimental drug for Alzheimer’s ...

An experimental Alzheimer's disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients ...

By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 6, 2026 (HealthDay News) — A mail-in blood test accurately detects markers ...